Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV001091875 | SCV001248135 | pathogenic | not provided | 2019-10-01 | criteria provided, single submitter | clinical testing | |
Cavalleri Lab, |
RCV001095580 | SCV001251213 | likely pathogenic | Polycystic kidney disease, adult type | 2020-02-05 | criteria provided, single submitter | research | PM1, PM2, PP3, PP4, PP5 |
Gene |
RCV001091875 | SCV001802385 | likely pathogenic | not provided | 2024-07-31 | criteria provided, single submitter | clinical testing | Published functional studies demonstrate a damaging effect as R2767C could disrupt the protein cleavage that is critical for the protein's function (PMID: 17574468); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 23431072, 17574468, 22508176, 31317121, 33454723) |
Victorian Clinical Genetics Services, |
RCV001095580 | SCV002767391 | pathogenic | Polycystic kidney disease, adult type | 2021-05-06 | criteria provided, single submitter | clinical testing | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with polycystic kidney disease 1 (MIM#173900). (I) 0107 - This gene is associated with autosomal dominant disease. Polycystic kidney disease 1 (MIM#173900) is predominantly caused by monoallelic variants, with rare reports of biallelic variants causing disease (OMIM). (I) 0200 - Variant is predicted to result in a missense amino acid change from arginine to cysteine. (I) 0251 - This variant is heterozygous. (I) 0301 - Variant is absent from gnomAD (both v2 and v3). (SP) 0309 - An alternative amino acid change at the same position has been observed in gnomAD (v2) (1 heterozygote, 0 homozygotes). (I) 0501 - Missense variant consistently predicted to be damaging by multiple in silico tools or highly conserved with a major amino acid change. (SP) 0600 - Variant is located in the annotated REJ domain (PMID: 17574468). (I) 0704 - Another missense variant comparable to the one identified in this case has limited previous evidence for pathogenicity. A different variant in the same codon resulting in a change to a proline has been shown to cause autosomal dominant polycystic kidney disease (ADPKD) (PMID: 22508176). (SP) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. This variant has been reported in individuals with ADPKD (ClinVar, PMID: 17574468, 22508176). (SP) 1002 - This variant has moderate functional evidence supporting abnormal protein function. Functional studies using transfected cells show that this variant disrupts polycyctin-1 cleavage (PMID: 17574468). (SP) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign |
Institute of Human Genetics, |
RCV001095580 | SCV004027771 | likely pathogenic | Polycystic kidney disease, adult type | 2023-05-12 | criteria provided, single submitter | clinical testing | Criteria applied: PM5_STR,PS4_MOD,PM1,PM2_SUP |
Mayo Clinic Laboratories, |
RCV001091875 | SCV005414319 | likely pathogenic | not provided | 2024-01-03 | criteria provided, single submitter | clinical testing | PM1, PM2, PS3_supporting, PS4 |
Fulgent Genetics, |
RCV001095580 | SCV005645125 | pathogenic | Polycystic kidney disease, adult type | 2024-04-29 | criteria provided, single submitter | clinical testing | |
Department of Pathology and Laboratory Medicine, |
RCV001292112 | SCV001480944 | pathogenic | Polycystic kidney disease | no assertion criteria provided | clinical testing | The PKD1 p.Arg2767Cys variant was identified in 4 of 1564 proband chromosomes (frequency: 0.003) from individuals or families with ADPKD (Audrezet 2012, Garcia-Gonzalez 2007). The variant was also identified in ADPKD Mutation Database (with highly likely pathogenic classification), database. The variant was identified by our laboratory in 1 individual with PKD in a family with this variant segregating in 2 individuals with the disease. The variant was not identified in dbSNP, ClinVar, Genesight-COGR, LOVD 3.0, PKD1-LOVD, databases. The variant was not identified in the 1000 Genomes Project, the NHLBI GO Exome Sequencing Project or the Exome Aggregation Consortium (August 8th 2016) control databases. The p.Arg2767 residue is conserved in mammals but not in more distantly related organisms, and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) suggest that the variant may impact the protein; however, this information is not predictive enough to assume pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict a difference in splicing. The variant is located with the Egg jelly receptor, REJ-like functional domain(s) increasing the likelihood that it may have clinical significance. In summary, based on the above information this variant meets our laboratory’s criteria to be classified as pathogenic. |